Ved Prakash Dwivedi
Overview
Explore the profile of Ved Prakash Dwivedi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ali W, Agarwal M, Jamal S, Gangwar R, Sharma R, Mubarak M, et al.
Int J Biol Macromol
. 2024 Aug;
278(Pt 3):134652.
PMID: 39173789
Despite the WHO's recommended treatment regimen, challenges such as patient non-adherence and the emergence of drug-resistant strains persist with TB claiming 1.5 million lives annually. In this study, we propose...
2.
Agarwal M, Bhaskar A, Singha B, Mukhopadhyay S, Pahuja I, Singh A, et al.
Commun Biol
. 2024 Aug;
7(1):949.
PMID: 39107377
The limitations of TB treatment are the long duration and immune-dampening effects of anti-tuberculosis therapy. The Cell wall plays a crucial role in survival and virulence; hence, enzymes involved in...
3.
Sahu D, Gupta C, Yennamalli R, Sharma S, Roy S, Hasan S, et al.
Sci Rep
. 2024 Jun;
14(1):14306.
PMID: 38907075
No abstract available.
4.
Sahu D, Gupta C, Yennamalli R, Sharma S, Roy S, Hasan S, et al.
Sci Rep
. 2024 Jun;
14(1):12935.
PMID: 38839973
The inhibition of tumor necrosis factor (TNF)-α trimer formation renders it inactive for binding to its receptors, thus mitigating the vicious cycle of inflammation. We designed a peptide (PIYLGGVFQ) that...
5.
Pahuja I, Ghoshal A, Okieh A, Verma A, Negi K, Agarwal M, et al.
Microbiol Spectr
. 2024 May;
12(7):e0041224.
PMID: 38809023
The host immune responses play a pivotal role in the establishment of long-term memory responses, which effectively aids in infection clearance. However, the prevailing anti-tuberculosis therapy, while aiming to combat...
6.
Mukhopadhyay S, Pahuja I, Okieh A, Pandey D, Yadav V, Bhaskar A, et al.
Tuberculosis (Edinb)
. 2024 May;
147:102517.
PMID: 38733881
The extensive inability of the BCG vaccine to produce long-term immune protection has not only accelerated the disease burden but also progressed towards the onset of drug resistance. In our...
7.
Ghoshal A, Verma A, Bhaskar A, Dwivedi V
Front Immunol
. 2024 Feb;
15:1339467.
PMID: 38312835
() effectively manipulates the host processes to establish the deadly respiratory disease, Tuberculosis (TB). has developed key mechanisms to disrupt the host cell health to combat immune responses and replicate...
8.
Ali W, Jamal S, Gangwar R, Ahmed F, Pahuja I, Sharma R, et al.
Microbes Infect
. 2023 Dec;
26(3):105284.
PMID: 38145750
The increasing prevalence of drug-resistant Tuberculosis (TB) is imposing extreme difficulties in controlling the TB infection rate globally, making treatment critically challenging. To combat the prevailing situation, it is crucial...
9.
Thakur M, Singh M, Kumar S, Dwivedi V, Dakal T, Yadav V
ACS Pharmacol Transl Sci
. 2023 Nov;
6(11):1600-1615.
PMID: 37974620
In the present era of the COVID-19 pandemic, viral infections remain a major cause of morbidity and mortality worldwide. In this day and age, viral infections are rampant and spreading...
10.
Singh B, Pahuja I, Yadav P, Shaji A, Chaturvedi S, Ranganathan A, et al.
J Infect Dis
. 2023 Oct;
229(5):1509-1518.
PMID: 37863472
Tuberculosis is the second leading infectious killer after coronavirus disease 2019 (COVID-19). Standard antitubercular drugs exhibit various limitations like toxicity, long treatment regimens, and lack of effect against dormant and...